Pulmonary Fibrosis Foundation Welcomes New Leadership
The Pulmonary Fibrosis Foundation (PFF) has taken an essential step in its mission by appointing Dr. Amy Hajari Case as its new Chief Medical Officer. Dr. Hajari Case, previously serving as the Director of the Interstitial Lung Disease Program at Piedmont Healthcare, has a rich background in pulmonary medicine and critical care. Her journey with the foundation began in 2020 as a Senior Medical Advisor for Education and Awareness.
A Dedicated Advocate for Patients
Known for her empathetic approach, Dr. Hajari Case has gained the respect of her peers and patients alike. David McNinch, President of the PFF Board of Directors, stated, "Dr. Hajari Case is respected by her peers and community as a thoughtful leader in education and communication for ILD patients." Her commitment to understanding and supporting patients has been pivotal in fostering trust within the PF community.
Vision for the Future of Pulmonary Fibrosis Care
Upon accepting her new role, Dr. Hajari Case expressed enthusiasm for leading the PFF at a critical juncture. "The PFF's mission to provide unparalleled support to patients and their loved ones while advancing research and development of novel treatments for pulmonary fibrosis is vitally important," she remarked. With a promising pipeline of therapeutic options, her leadership will be instrumental in navigating the evolving landscape of PF treatment.
Building on Experience and Expertise
Dr. Hajari Case's educational background is extensive. She holds board certifications in pulmonary disease and critical care medicine, and she is a distinguished member of the American Thoracic Society, as well as a fellow of the American College of Chest Physicians. Her clinical expertise encompasses the diagnosis and management of interstitial lung diseases, and she is currently the principal investigator for various clinical trials focused on pulmonary fibrosis.
Engaging Patients in Clinical Trials
Scott Staszak, President and CEO of the PFF, highlighted Dr. Hajari Case’s impending contributions, stating, "Dr. Hajari Case will play a key role in developing the PFF's strategic plan, including initiatives to engage patients in clinical trials." As the healthcare field rapidly advances, particularly with the integration of artificial intelligence in patient care and research, the PFF is poised for significant growth under her guidance.
The Importance of Raising Awareness
With over 250,000 individuals affected by pulmonary fibrosis and related diseases in the country, the need for awareness and education is greater than ever. These conditions cause serious inflammation and scarring in the lungs, affecting the body's ability to absorb oxygen effectively. The increasing prevalence of pulmonary fibrosis, with over 50,000 new diagnoses annually, underscores the need for dedicated leadership in patient care and research.
About the Pulmonary Fibrosis Foundation
The Pulmonary Fibrosis Foundation is dedicated to accelerating the development of new treatments and ultimately finding a cure for pulmonary fibrosis. Until that day comes, the organization is committed to enhancing the care of patients and offering unparalleled support and educational resources to patients, caregivers, and healthcare providers. The PFF holds a four-star rating from Charity Navigator and is accredited by the Better Business Bureau (BBB) Wise Giving Alliance, further highlighting its commitment to excellence.
Frequently Asked Questions
Who has been appointed as the new Chief Medical Officer of PFF?
Dr. Amy Hajari Case has been appointed as the Chief Medical Officer of the Pulmonary Fibrosis Foundation.
What significant experience does Dr. Hajari Case bring to the PFF?
Dr. Hajari Case has extensive experience in pulmonary disease and critical care, having served at Piedmont Healthcare and holding multiple board certifications.
What is the mission of the Pulmonary Fibrosis Foundation?
The mission of the PFF is to advance care for pulmonary fibrosis patients while striving to find new treatments and a potential cure for the disease.
Why is the role of Chief Medical Officer important for the PFF?
The Chief Medical Officer plays a crucial role in guiding the foundation's strategies, including patient engagement in clinical trials, which supports research and advancements in treatment.
How does pulmonary fibrosis impact individuals’ health?
Pulmonary fibrosis and related interstitial lung diseases can cause significant damage to the lungs, impacting one’s ability to breathe and absorb oxygen, with a growing number of diagnoses occurring annually.
